Pfizer - Roivant tie-up generates positive mid-stage data for lead asset
Source: SeekingAlpha
2026-02-06 09:02:17 ET
More on Pfizer, Roivant Sciences
- Pfizer Inc. 2025 Q4 - Results - Earnings Call Presentation
- Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
- Pfizer: Messy Q4 Earnings Mask An Improving Business
- Pfizer wins FDA priority review for Hympavzi label expansion
- Large-cap stocks with lowest dividend growth grade
Read the full article on Seeking Alpha
For further details see:
Pfizer – Roivant tie-up generates positive mid-stage data for lead asset
Roivant Sciences Ltd.
NASDAQ: ROIV
ROIV Trading
-5.27% G/L:
$28.385 Last:
920,686 Volume:
$29.23 Open:
ROIV Latest News
March 04, 2026 11:42:41 pm
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
ROIV Stock Data
$19,574,426,097
449,460,314
0.77%
170
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
